Epizyme (EPZM -5.9%) slips on average volume as broad market selling weighs on shares. The stock had rallied over 70% since early October before today’s action.
The FDA’s Oncologic Drugs Advisory Committee will meet on Wednesday, December 18, to review and discuss the company’s marketing application seeking accelerated approval of tazemetostat for metastatic or locally advanced epithelioid sarcoma patients not eligible for curative surgery.
The agency’s action date is January 23, 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.